Blood Test to Detect Early-Onset Colorectal Cancer
Tests a non-invasive blood test to detect colorectal cancer in adults under 50.
Plain-language title generated from the registry record
Registry title: Early Onset Colorectal Cancer Detection
Key facts
- Where
- Barcelona, Madrid, Salamanca, and San Cristóbal de La Laguna, SpainSee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with colorectal cancer diagnosed before age 50, and also people shown by colonoscopy to be free of cancer. It tests a blood test for early-onset colorectal cancer.
- Age
- 18 to 50 years
- Sex
- All sexes can join.
- Disease stage
- Stage I, II, III or IV colorectal cancer, diagnosed before age 50. Cancer-free people can join as controls.
- Earlier treatment
- For people with cancer, at least one blood sample must have been taken before any treatment meant to remove all of the disease.
Main reasons for not taking part
- Hereditary colorectal cancer syndromes found by genetic testing
- Inflammatory bowel diseases
- No written informed consent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 50 years old?
Source: NCT06342401, who can take part
Where in Spain
- Barcelona UniversityBarcelona, SpainContact: Francesc Balaguer, MD, PhDTaking people
- Colorectal Surgery, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona UABBarcelona, SpainContact: Marc Martí-GallostraTaking people
- Surgery Department, Hospital del Mar, Barcelona, SpainBarcelona, SpainContact: Marta Jiménez-ToscanoTaking people
- Salamanca Biomedical Research InstituteMadrid, SpainContact: Jose Perea, MDTaking people
- University of Salamanca-SACYL-CSIC, Salamanca, SpainSalamanca, SpainContact: Rosario Vidal-TocinoTaking people
- University of La LagunaSan Cristóbal de La Laguna, SpainContact: Ajay Goel, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- City of Hope Medical Center
- Trial code
- NCT06342401
- Record updated
- 7 July 2026
- Original description
Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women.Read full original descriptionShow less
Development and Validation fo an Exosome-Based and Machine Learning Powered Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) once predominantly affected older individuals, but in recent years has witnessed a progressive increase in incidence among young adults. Once rare, early-onset colorectal cancer (EOCRC, that is, a CRC diagnosed before the age of 50) now constitutes 10-15% of all newly diagnosed CRC cases and it stands as the first cause of cancer-related death in young men and the second for young women.
This study aims to detect EOCRC with a non-invasive test, using a blood-based molecular assay based on microRNA (ribonucleic acid)
Inclusion: Stage I, II, III, IV colorectal cancer (TNM classification, 8th edition) diagnosed before the age of 50 (EOCRC cases); Received standard diagnostic and staging procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment; Colonoscopy-proven cancer-free status at the time of study inclusion (Non-disease controls).
Exclusion: Hereditary colorectal cancer syndromes (identified through genetic testing); Inflammatory bowel diseases; Lack of written informed consent.